This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At Medicarians 2025, MedCity News Editor-in-Chief Arundhati Parmar explored the state of AgeTech venture capital with three investors. The panelists agreed that despite growing clear opportunities, the AgeTech market currently lacks the dedicated funding, proven business models and major success stories needed for it to take off. The post Where Does AgeTech Investment Stand?
3D screen printing provides innovative drug development capabilities that are difficult or impossible to achieve with traditional methods, including complex multi-layered formulations, precision control over drug release profiles, and near-endless possibilities in the geometric shaping of dosage forms. In this article, learn how 3D screen printing offers unmatched flexibility to tailor formulations for specific therapeutic needs and redefines whats possible in drug development and manufacturing.
Even as studies and personal experiences repeatedly reflect the effectiveness of MOUD, a stigma about this approach and the medication persists, complicating efforts to help more people treat their opioid use disorders. The post Stigma Against Addiction Medication Limits Our Ability to End the Opioid Epidemic appeared first on MedCity News.
Can pharma brands remain relevant in a digital-first healthcare economy? As the industry pivots toward patient empowerment, AI-enabled solutions, and content-driven search, the real challenge isnt visibilityits authority. Much like the shift from blockbuster drugs to targeted therapies, digital transformation demands new approaches. In this article, well unpack the most effective SEO marketing strategies that align with pharma brands and the 2025 shifting strategyhelping you drive organic traffi
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
The combination of Bristol Myers Squibb cancer drugs Opdivo and Yervoy landed FDA approvals for the first-line treatment of colorectal cancer and hepatocellular carcinoma. Several other products also expanded their approved uses in our recap of recent regulatory news. The post BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week appeared first on MedCity News.
The goal of the Two-Midnight Rule, originally introduced under traditional Medicare Part A, was to reduce hospital admissions and to ensure the appropriate use of inpatient versus outpatient observation status. Here are some challenges and best practices. The post Navigating Medicare Advantage Compliance One Year After the Two-Midnight Rule appeared first on MedCity News.
The goal of the Two-Midnight Rule, originally introduced under traditional Medicare Part A, was to reduce hospital admissions and to ensure the appropriate use of inpatient versus outpatient observation status. Here are some challenges and best practices. The post Navigating Medicare Advantage Compliance One Year After the Two-Midnight Rule appeared first on MedCity News.
Cigna Healthcare ranks highest among commercial health plans when it comes to digital experience, while UPMC Health Plan ranks highest among Medicare Advantage plans, according to J.D. Power. The post Which Health Plans Take the Lead in Member Digital Experience? appeared first on MedCity News.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content